Cargando…
Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance
BACKGROUND: Steroid receptor coactivator 3 (SRC3) is an important coactivator of a number of transcription factors and is associated with a poor outcome in numerous tumours. Steroid receptor coactivator 3 is amplified in 25% of epithelial ovarian cancers (EOCs) and its expression is higher in EOCs c...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670494/ https://www.ncbi.nlm.nih.gov/pubmed/23652306 http://dx.doi.org/10.1038/bjc.2013.199 |
_version_ | 1782271858203164672 |
---|---|
author | Palmieri, C Gojis, O Rudraraju, B Stamp-Vincent, C Wilson, D Langdon, S Gourley, C Faratian, D |
author_facet | Palmieri, C Gojis, O Rudraraju, B Stamp-Vincent, C Wilson, D Langdon, S Gourley, C Faratian, D |
author_sort | Palmieri, C |
collection | PubMed |
description | BACKGROUND: Steroid receptor coactivator 3 (SRC3) is an important coactivator of a number of transcription factors and is associated with a poor outcome in numerous tumours. Steroid receptor coactivator 3 is amplified in 25% of epithelial ovarian cancers (EOCs) and its expression is higher in EOCs compared with non-malignant tissue. No data is currently available with regard to the expression of SRC-3 in EOC and its influence on outcome or the efficacy of treatment. METHODS: Immunohistochemistry was performed for SRC3, oestrogen receptor-α, HER2, PAX2 and PAR6, and protein expression was quantified using automated quantitative immunofluorescence (AQUA) in 471 EOCs treated between 1991 and 2006 with cytoreductive surgery followed by first-line treatment platinum-based therapy, with or without a taxane. RESULTS: Steroid receptor coactivator 3 expression was significantly associated with advanced stage and was an independent prognostic marker. High expression of SRC3 identified patients who have a significantly poorer survival with single-agent carboplatin chemotherapy, while with carboplatin/paclitaxel treatment such a difference was not seen. CONCLUSION: Steroid receptor coactivator 3 is a poor prognostic factor in EOCs and appears to identify a population of patients who would benefit from the addition of taxanes to their chemotherapy regimen, due to intrinsic resistance to platinum therapy. |
format | Online Article Text |
id | pubmed-3670494 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-36704942014-05-28 Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance Palmieri, C Gojis, O Rudraraju, B Stamp-Vincent, C Wilson, D Langdon, S Gourley, C Faratian, D Br J Cancer Molecular Diagnostics BACKGROUND: Steroid receptor coactivator 3 (SRC3) is an important coactivator of a number of transcription factors and is associated with a poor outcome in numerous tumours. Steroid receptor coactivator 3 is amplified in 25% of epithelial ovarian cancers (EOCs) and its expression is higher in EOCs compared with non-malignant tissue. No data is currently available with regard to the expression of SRC-3 in EOC and its influence on outcome or the efficacy of treatment. METHODS: Immunohistochemistry was performed for SRC3, oestrogen receptor-α, HER2, PAX2 and PAR6, and protein expression was quantified using automated quantitative immunofluorescence (AQUA) in 471 EOCs treated between 1991 and 2006 with cytoreductive surgery followed by first-line treatment platinum-based therapy, with or without a taxane. RESULTS: Steroid receptor coactivator 3 expression was significantly associated with advanced stage and was an independent prognostic marker. High expression of SRC3 identified patients who have a significantly poorer survival with single-agent carboplatin chemotherapy, while with carboplatin/paclitaxel treatment such a difference was not seen. CONCLUSION: Steroid receptor coactivator 3 is a poor prognostic factor in EOCs and appears to identify a population of patients who would benefit from the addition of taxanes to their chemotherapy regimen, due to intrinsic resistance to platinum therapy. Nature Publishing Group 2013-05-28 2013-05-07 /pmc/articles/PMC3670494/ /pubmed/23652306 http://dx.doi.org/10.1038/bjc.2013.199 Text en Copyright © 2013 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Molecular Diagnostics Palmieri, C Gojis, O Rudraraju, B Stamp-Vincent, C Wilson, D Langdon, S Gourley, C Faratian, D Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance |
title | Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance |
title_full | Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance |
title_fullStr | Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance |
title_full_unstemmed | Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance |
title_short | Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance |
title_sort | expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance |
topic | Molecular Diagnostics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670494/ https://www.ncbi.nlm.nih.gov/pubmed/23652306 http://dx.doi.org/10.1038/bjc.2013.199 |
work_keys_str_mv | AT palmieric expressionofsteroidreceptorcoactivator3inovarianepithelialcancerisapoorprognosticfactorandamarkerforplatinumresistance AT gojiso expressionofsteroidreceptorcoactivator3inovarianepithelialcancerisapoorprognosticfactorandamarkerforplatinumresistance AT rudrarajub expressionofsteroidreceptorcoactivator3inovarianepithelialcancerisapoorprognosticfactorandamarkerforplatinumresistance AT stampvincentc expressionofsteroidreceptorcoactivator3inovarianepithelialcancerisapoorprognosticfactorandamarkerforplatinumresistance AT wilsond expressionofsteroidreceptorcoactivator3inovarianepithelialcancerisapoorprognosticfactorandamarkerforplatinumresistance AT langdons expressionofsteroidreceptorcoactivator3inovarianepithelialcancerisapoorprognosticfactorandamarkerforplatinumresistance AT gourleyc expressionofsteroidreceptorcoactivator3inovarianepithelialcancerisapoorprognosticfactorandamarkerforplatinumresistance AT faratiand expressionofsteroidreceptorcoactivator3inovarianepithelialcancerisapoorprognosticfactorandamarkerforplatinumresistance |